News headlines about NephroGenex (NASDAQ:NRX) have been trending somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research firm identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. NephroGenex earned a daily sentiment score of 0.13 on Accern’s scale. Accern also assigned news articles about the healthcare company an impact score of 45.5817911358747 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Shares of NephroGenex (NRX) opened at 0.1401 on Tuesday. The stock has a 50 day moving average price of $0.40 and a 200-day moving average price of $1.17. NephroGenex has a 52-week low of $0.10 and a 52-week high of $8.90.
ILLEGAL ACTIVITY NOTICE: This piece was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this piece on another website, it was illegally stolen and republished in violation of international trademark & copyright laws. The legal version of this piece can be viewed at https://ledgergazette.com/2017/10/10/nephrogenex-nrx-earns-daily-media-sentiment-score-of-0-13.html.
NephroGenex, Inc is a pharmaceutical company. The Company is focused on the development of therapeutics to treat kidney disease. The Company has paused the clinical program of its product candidate, oral Pyridorin, for the treatment of diabetic nephropathy. The Company was primarily focused on the Phase III Pyridorin program, and other planned clinical and nonclinical studies and other work needed to submit Pyridorin for acute kidney injury (AKI), as well as the treatment of diabetic nephropathy in patients with Type II diabetes for regulatory approval in the United States and Europe.
Receive News & Ratings for NephroGenex Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NephroGenex Inc and related companies with MarketBeat.com's FREE daily email newsletter.